Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th May 20267:00 amRNSUS$3.8m Order for Guardian BdMS
6th May 20267:00 amRNSQ3 FY2026 Quarterly KPIs
20th Apr 202612:30 pmRNSHolding(s) in Company
10th Apr 20268:53 amRNSStatement re alleged cyber threat
27th Mar 20267:00 amRNSHalf-year Financial Report
24th Feb 20267:00 amRNS-RPublication of Investor Presentation
18th Feb 20267:00 amRNSTrading Update - H1 FY2026
13th Feb 20267:30 amRNSAppointment of Joint Broker
11th Feb 20267:00 amRNSQ2 FY2026 Quarterly KPIs
13th Jan 202612:00 pmRNS-R3D Cabin Perception Mapping breaks new ground
6th Jan 20267:00 amRNSAgreement
5th Jan 20267:00 amRNSHolding(s) in Company
5th Jan 20267:00 amRNS-R3D Cabin Perception Mapping to be unveiled at CES
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
17th Dec 20257:00 amRNS-RTechnical Paper Series - Intoxication launched
4th Dec 20257:00 amRNS-RSeeing Machines 2025 Guardian Insights Report
27th Nov 20257:00 amRNSResults of AGM
26th Nov 20257:30 amRNSJapanese Auto Award and Extended European Program
12th Nov 20257:05 amRNSQ1 FY2026 Quarterly KPIs
12th Nov 20257:00 amRNSGuardian order from US-based multinational company
6th Nov 20257:05 amRNS-RCollaboration with Magna milestone in China
3rd Nov 20257:00 amRNSBoard Changes
3rd Nov 20257:00 amRNSNotice of Annual General Meeting
30th Oct 20257:00 amRNSLATAM Distributor Orders 1,300 Guardian Units
29th Oct 20257:00 amRNSAdvanced Development Project with Japanese OEM
8th Oct 20257:00 amRNSUS$1.8m expansion order for Guardian BdMS
26th Sep 20257:00 amRNSExpanding Guardian prospects across Europe
25th Sep 20257:00 amRNSFY2025 Results and Annual Financial Report
24th Sep 20257:20 amRNSFirst Guardian contract through Mitsubishi
10th Sep 20257:05 amRNS-RSeeing Machines Launches Impairment Capability
10th Sep 20257:00 amRNSNotice of Results and Presentation
29th Aug 202510:10 amRNSDirector Dealing
21st Aug 20257:00 amRNSFY2025 Trading Update
5th Aug 20257:00 amRNSQ4 FY2025 Quarterly KPIs
30th Jun 20257:00 amRNSMitsubishi Electric Europe Guardian collaboration
27th Jun 20257:00 amRNSUS Guardian Gen 3 trial with Mitsubishi Electric
16th Jun 20258:59 amRNS$1.2 Million Agreement with Global Auto Leader
9th May 20252:31 pmRNSDirector dealing
1st May 20257:00 amRNSQ3 FY2025 Quarterly KPIs
29th Apr 20259:58 amRNSNotification of Major Holdings
8th Apr 20258:53 amRNSHoldings in Company
8th Apr 20257:00 amRNSDirector/PDMR Shareholding
4th Apr 20257:00 amRNSDirector dealing
2nd Apr 202511:00 amRNSLondon presentation for investors and analysts
2nd Apr 20257:00 amRNSDirector dealing
2nd Apr 20257:00 amRNSDirector dealing
1st Apr 202512:00 pmRNS-RSeeing Machines Announces 3D Camera Technology
31st Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Mar 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.